TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01024582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: before treatment a biopsy will be taken to confirm breast cancer type

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fine-needle aspiration
Description: at FNA tumor material will be collected and fresh frozen for micro-analyses; parafin embedded tissue will bestored for tissue-array analysis

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: accelerated partial breast irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: image-guided radiation therapy
Study: NCT01967823

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-NY ESO-1 mTCR PBL
Description: Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenously (IV) in 250 mL dextrose 5% in water (D5W) infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg /m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg intravenously (IV) (based on total body weight) over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
Study: NCT04138823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 891065
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 891065
Description: film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 891065
Description: film-coated tablets
Study: NCT02394093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin (Acetylsalicylic acid, BAYe4465)
Description: One stick pack containing 500 mg acetylsalicylic acid dry powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin (Acetylsalicylic acid, BAYe4465)
Description: One tablet containing 500 mg acetylsalicylic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin (Acetylsalicylic acid, BAYe4465)
Description: One effervescent tablet containing 500 mg acetylsalicylic acid
Study: NCT03848390

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional diet
Description: The conventional diet arm will be asked to consume a hypocaloric diet, and they will be allowed to eat at any time of the day with no time restriction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Time-restricted Feeding
Description: The modified time-restricted feeding arm will be asked to consume any food but will be asked to consume this food for only a 9 hour daytime period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: At least 30 minutes of physical activity per day 5 times per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: At least 30 minutes of physical activity per day 5 times per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Restricted consumption of sweetened beverages
Description: Restricted consumption of juice, soda, and other sweetened beverages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restricted consumption of sweetened beverages
Description: Restricted consumption of juice, soda, and other sweetened beverages.
Study: NCT03750292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEPAirX air filter
Description: It is a trademarked, patented (U.S. Patent # 7,802,443), U.S. FDA approved Class II medical re-circulating air cleaner, built by Air Innovations, Inc. (North Syracuse, NY) to provide improved indoor air quality in the bedrooms of asthmatic children. Units to be used in the proposed study have a 99.97% efficient filter for particles 0.3 µm in size. The device provides a clean air delivery rate (CADR) of 9 per hour with 1.8 of them being outdoor air.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: control air filter
Description: A placebo mode was added to the HEPAirX to provide only recirculation (without filtration or ventilation using outdoor air) and temperature control of the room air. The placebo filter is made of metal.
Study: NCT01062711

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey or soy protein
Description: Whey and casein are isolated milk proteins

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey or soy protein
Description: Whey and casein are isolated milk proteins

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey or soy protein
Description: Whey and casein are isolated milk proteins

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey or soy protein
Description: Whey and casein are isolated milk proteins

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey or soy protein
Description: Whey and casein are isolated milk proteins
Study: NCT00920985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE (FC Patch Low, BAY86-5016)
Description: 21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 7 cycles and placebo tablets matching the conditions of the treatment of Arm 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A
Description: 21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 7 cycles and placebo patches matching the conditions of the treatment of Arm 1
Study: NCT04493411

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WBMRI
Description: WBMRI will be performed either at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points.~1. Baseline: (before or after 1-2 cycles of induction therapy)~2. Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy)~3. Between Week 24 - 36 (before starting maintenance therapy)~4. Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography/Computed Tomography (PET/CT)
Description: PET/CT will be performed at at 1 time point for cross-sectional study or at 4 timepoints for the longitudinal study at the following time points.~1. Baseline: (before or after 1-2 cycles of induction therapy)~2. Between Week 12 - 24 (before Bone Marrow Transplant or undergoing consolidation therapy)~3. Between Week 24 - 36 (before starting maintenance therapy)~4. Between Week 60 - 72 (post bone marrow transplant or consolidation therapy and after approximately 9 months of maintenance therapy)
Study: NCT01774240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: systematic screening and treatment of delirium
Description: systematic screening for delirium with DOS scale and CAM ICU. In case of delirium, treatment according to guidelines.
Study: NCT02597166

Intervention type: DRUG
Group type: OTHER
Intervention: Ledipasvir/Sofosbuvir
Description: Each tablet of Harvoni contains 90 mg ledipasvir and 400 mg sofosbuvir.
Study: NCT03605147

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CaHMB
Description: Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by abdominal CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.
Study: NCT03859518

Intervention type: OTHER
Intervention: blood and skin samples
Description: To study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.

Intervention type: OTHER
Intervention: blood and skin samples
Description: To study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.
Study: NCT01431937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK2018682
Description: Active Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01615055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: 20-40 mg fluoxetine po qd for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20-40 mg pharmacologically inactive tablets for 6 months
Study: NCT04113174

Intervention type: OTHER
Intervention: Decision Analytic Modelling
Description: Prognostic models will be translated into a framework to guide clinical decision making by identifying relevant thresholds of predicted risk, above which implementation of our stated interventions is warranted.

Intervention type: OTHER
Intervention: Decision Analytic Modelling
Description: Prognostic models will be translated into a framework to guide clinical decision making by identifying relevant thresholds of predicted risk, above which implementation of our stated interventions is warranted.

Intervention type: OTHER
Intervention: Decision Analytic Modelling
Description: Prognostic models will be translated into a framework to guide clinical decision making by identifying relevant thresholds of predicted risk, above which implementation of our stated interventions is warranted.
Study: NCT01062711

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey or soy protein
Description: Whey and casein are isolated milk proteins

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey or soy protein
Description: Whey and casein are isolated milk proteins
Study: NCT00912613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICU Diary
Description: ICU Diary containing daily information of patients condition and treatment with appropriate photographs
Study: NCT02896790

Intervention type: OTHER
Intervention: Interviews with 2 oncologists and 10 patients

Intervention type: OTHER
Intervention: Interviews with 15 patients
Study: NCT04140162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Induction: 16 mg/kg actual body weight IV weekly (weeks 1-8; total of 8 doses) then every 2 weeks (weeks 9-24; total of 8 doses).~Consolidation: 16 mg/kg actual body weight IV every four weeks (weeks 25-36)~Maintenance: 16 mg/kg actual body weight IV every eight weeks (weeks 37-88)~Sites will continue to use IV daratumumab to treat existing study patients until the IV daratumumab stock on site has been exhausted. The sites will then transition existing patient to SQ daratumumab. New patients will be started on SQ 1800mg daratumumab.~Induction- Cycles 1-2 (days 1, 8,15, 22), Cycles 3-6 (Weeks 9-24- two weeks (days 1, 15 ) Consolidation- Every 4 weeks on day 1 Maintenance- Every 8 weeks on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Induction: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 1-24)~Consolidation: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 25-36)~Maintenance: 10 mg PO once daily, on days 1-21 of each 28-day cycle until progression or intolerance~Maintenance: 10 mg PO once daily, on days 1-21, weeks 37+ until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Consolidation: 1.5 mg/m2 SQ on day 1, 8, 15 and 22 of each 28-day cycle (weeks 25-36)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction and Consolidation: 40 mg (or reduced dose of 20 mg) PO or IV weekly
Study: NCT04201626

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adapted ERAS
Description: Each woman in the intervention group will attend a preoperative counseling session with nurse and doctors. In addition to the standard preoperative counseling, explaining the purpose, process, and the importance of ERAS protocol compliance will be added to the session. Preoperative nutrition and laboratory assessment will be done according to adapted ERAS protocol on that same visit.~During admission, the intervention group participants are provided with care according to adapted ERAS protocol including no bowel preparation, no extended fasting before surgery, balanced intravenous crystalloid, thromboprophylaxis, multimodal pain control reducing opioid usage, multimodal anti-emetics medications, stepping diet up to regular diet within 24 hours, chewing gum for post-operative ileus prevention, early removal of Foley's catheter, and promote early ambulation using care checklist plan.
Study: NCT04113174

Intervention type: OTHER
Intervention: Decision Analytic Modelling
Description: Prognostic models will be translated into a framework to guide clinical decision making by identifying relevant thresholds of predicted risk, above which implementation of our stated interventions is warranted.
Study: NCT04643639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb hemoperfusion
Description: Subjects will be treated with CytoSorb hemoperfusion (in stand-alone setup) for 6 hours at a flow rate of 250 ml/min during endotoxemia.
Study: NCT01752790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Top-down
Description: Patients randomized to top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus AZA (2 mg/Kg per os/day). Patients who will not respond to the induction regimen at week 8 will receive no further treatment with infliximab. Disease recurrences will be treated with infliximab (reduction of the interval between two doses). At 12 months pazients will discontinue azathioprine and continue infliximab (5mg/kg every 8 weeks). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Step-up
Description: Patients randomized on Step-up arm will receive methylprednisolone (1 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day).Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
Study: NCT00503334

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: preOP booster (oral nutritional supplement, food for special medical purposes)
Description: 3x1 dosage pre-operatively

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: preOP booster (oral nutritional supplement, food for special medical purposes)
Description: 3x1 dosage pre-operatively
Study: NCT03212417

Intervention type: OTHER
Group type: OTHER
Intervention: Educational intervention
Description: Presentation of risk factors, signs and symptoms, and interventions on compassion fatigue
Study: NCT02976025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Longitudinal Remote Consultation
Description: Longitudinal Remote Consultation utilizes video conferencing to efficiently link providers to consultants who provide timely feedback and training in collaborative care. LRC will be provided in addition to standard collaborative care training and support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collaborative Care
Description: Standard collaborative care implementation training and support.
Study: NCT02253056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting / Caloric Restriction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Diet
Study: NCT02276118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: device: e.motion PS Pro
Description: patients will undergo total knee arthroplasty with e.motion PS Pro implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: device : Genesis II
Description: patients will undergo total knee arthroplasty with Genesis II implant
Study: NCT03927313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: For both experimental arms: 1.2g linezolid 28 days, followed by 600mg linezolid for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: For both experimental arms: 1.2g linezolid 28 days, followed by 600mg linezolid for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose rifampicin
Description: For both experimental arms: additional 25mg/kg (making a total of 35mg/kg) rifampicin, for the first 56 days of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose rifampicin
Description: For both experimental arms: additional 25mg/kg (making a total of 35mg/kg) rifampicin, for the first 56 days of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: For only one of the experimental arms: 1000mg of aspirin daily for 56 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care anti-tuberculous therapy
Description: 10mg/kg oral rifampicin, 5mg/kg oral isoniazid, 15mg/kg oral ethambutol, 25mg/kg oral pyrazinamide daily for 56 days.
Study: NCT01425411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan
Description: 80/160 mg dosage of valsartan or 160+12,5 mg valsartan+hydrochlorothiazide combination, once a day, for six months
Study: NCT03874273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib 280mg/m2 twice a day (for 24 months maximum)
Study: NCT03775044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medherent Device
Description: The Medherent Medication Management Device (MMD) is intended to enable patients to self-manage their medication at home when it may otherwise require assistance.
Study: NCT01831258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SensAwake On

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SensAwake Off
Study: NCT03927313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care anti-tuberculous therapy
Description: 10mg/kg oral rifampicin, 5mg/kg oral isoniazid, 15mg/kg oral ethambutol, 25mg/kg oral pyrazinamide daily for 56 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care anti-tuberculous therapy
Description: 10mg/kg oral rifampicin, 5mg/kg oral isoniazid, 15mg/kg oral ethambutol, 25mg/kg oral pyrazinamide daily for 56 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone according to doses of Thwaites criteria for the first 8 weeks of anti-tuberculous treatment. Doses differ according to participants Medical Research Council (MRC) grade. Given orally if participant can swallow and intravenously if they cannot.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone according to doses of Thwaites criteria for the first 8 weeks of anti-tuberculous treatment. Doses differ according to participants Medical Research Council (MRC) grade. Given orally if participant can swallow and intravenously if they cannot.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone according to doses of Thwaites criteria for the first 8 weeks of anti-tuberculous treatment. Doses differ according to participants Medical Research Council (MRC) grade. Given orally if participant can swallow and intravenously if they cannot.
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Zopiclone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Zopiclone
Study: NCT03605147

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.
Study: NCT04569136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: The education session including education about mastitis, feeding techniques, lifestyle changes, thermal/cryo therapy and demonstration of breast self-massage will take approximately 20 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Education
Description: The education session including education about mastitis, feeding techniques, lifestyle changes, thermal/cryo therapy and demonstration of breast self-massage will take approximately 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Description: Participants will be treated with 5 minutes of therapeutic ultrasound (pulsed mode) at a frequency of 1 Mega Hertz, a duty cycle of 20%, a pulse intensity of 1.8 Watt/centimetre squared. The ultrasound probe will be moved at a speed of about 4 centimetre/second. The intensity and duration will be adjusted if the patient complains of discomfort. The ultrasound transducer head will massage over the tender point on the breast.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham ultrasound
Description: Participants will receive 5 minutes of 'sham' ultrasound at 0 Watt/centimetre squared intensity from a physical therapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast massage
Description: Breast massage includes general and focused massage. Participants will lie in supine position. The breast massage will be applied according to the Vodder method to the affected breast.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Breast massage
Description: Breast massage includes general and focused massage. Participants will lie in supine position. The breast massage will be applied according to the Vodder method to the affected breast.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual obstetric care
Description: Usual obstetric care may include verbal advice/printed patient information regarding mastitis and breastfeeding from the medical or nursing staff.
Study: NCT03780478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerve block
Description: 0.25% bupivacaine with epinephrine (1:100k), with total volume of 2mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Saline Injection
Description: Saline injection, total volume 2ml
Study: NCT00607711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral palifosfamide tris
Description: Capsule(s) given daily for 15 days followed by a 6 day rest. This is a dose escalation arm.